915006-41-6

Basic information

• Product Name: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide
• Synonyms: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide
• CAS NO: 915006-41-6
• Molecular Weight: 585.843
• Mol File: 915006-41-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide(915006-41-6)
• EPA Substance Registry System: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-(2-tert-butylsulfamoyl-ethyl)-2-cyclohex-1-enyl-phenyl]-amide(915006-41-6)

Safety Data

• Hazardous Substances Data: 915006-41-6(Hazardous Substances Data)

Upstream product

• 915006-40-5 2-(4-amino-3-cyclohex-1-enyl-phenyl)-ethanesulfonic acid tert-butylamide 
• 915006-38-1 2-(4-nitro-phenyl)-ethanesulfonic acid tert-butylamide 
• 915006-39-2 2-(4-amino-phenyl)-ethanesulfonic acid tert-butylamide 
• 915006-37-0 2-(4-amino-3-bromo-phenyl)-ethanesulfonic acid tert-butylamide 
• 80259-15-0 2-(4-nitro-phenyl)ethanesulfonyl chloride 
• 854044-52-3 ethyl 4-cyano-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazole-2-carboxylate 

Relevant articles and documents

Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.